一种类型的糖原储存疾病病例
Lingying Dan1,2, Xiaoxiao Song3, Hanxiao Yu4
1Department of Endocrinology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. 451579221@qq.com.
概括
本案例研究强调了一名年轻男性被诊断患有甲型糖原储存疾病,通过基因检测发现了G6PC基因突变. 管理高粉饮食和药物稳定了他的病情,解决了痛风和饥饿症状.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 遗传学 遗传学是一种遗传学.
- 临床医学 临床医学
背景情况:
- 糖原储存疾病Ia型 (GSD Ia) 是一种罕见的遗传代谢障碍.
- GSD Ia可以呈现出各种临床表现,包括代谢障碍和痛风等并发症.
- 早期诊断和适当的治疗对于改善患者的治疗结果至关重要.
研究的目的:
- 报告一个GSD Ia病例,呈现出复发性痛风性关节炎和高脂血症.
- 详细说明诊断过程,包括成像,生物化学测试和遗传分析.
- 为了说明饮食和药理干预措施在管理GSD Ia方面的有效性.
主要方法:
- 分析了临床表现和实验室发现.
- 双能量CT扫描被用于成像痛风石.
- 进行肝脏活检和G6PC基因测序以确定确诊.
主要成果:
- 该患者出现了复发性痛风,高脂血症和低血糖症.
- CT扫描显示了脚关节中的痛风托菲.
- 基因分析证实了G6PC基因 (c.248G>A和c.238T>A) 中的复合异构基因突变.
- 用高粉饮食和降脂疗法治疗导致临床稳定和症状改善.
结论:
- 这一案例强调了在患有不明原因代谢异常和痛风的患者中考虑GSD Ia的重要性.
- 基因检测对于确认GSD Ia的诊断至关重要.
- 涉及饮食修改和药物治疗的多学科方法有效地管理GSD Ia及其并发症.
相关概念视频
Inborn Errors of Metabolism
207
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
207
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Glucose Transporters
23.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.4K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306


